31 January 2023>: Clinical Research
A Retrospective Study to Evaluate the Association Between the Glasgow Prognostic Score and Atrial Fibrillation, Stroke, and Mortality at 30 Days and at 1 Year After Coronary Artery Bypass Graft Surgery
Esra Dönmez 1ABCDEF* , Sevgi Özcan 1ABCDEF , Bülent Mert 2BCD , Berk Özkaynak 2ABDF , Sevil Tuğrul 1ABC , İrfan Şahin 1ABDEF , Ertuğrul Okuyan 1AEFDOI: 10.12659/MSM.939283
Med Sci Monit 2023; 29:e939283
Table 2 Comparison of demographic, laboratory, and clinical parameters with respect to 30-day cardiovascular mortality.
Variables | Survivor n=671 | Non-survivor n=40 | p |
---|---|---|---|
Age | 60.1±9.6 | 63.5±11.05 | |
Body mass index (kg/m) | 27.8±4.5 | 28.8±4.2 | 0.209 |
EuroSCORE II | 1.9±1.1 | 3.3±1.3 | |
History of hypertension, n (%) | 349 (51.9) | 23 (57.5) | 0.494 |
History of CVA, n (%) | 23 (3.4) | 2 (5) | 0.416 |
History of COPD, n (%) | 120 (17.8) | 15 (37.5) | |
History of DM, n (%) | 279 (41.5) | 16 (40) | 0.850 |
History of CAD, n (%) | 175 (26.2) | 14 (35.9) | 0.181 |
History of carotid artery disease, n (%) | 50 (7.5) | 9 (22.5) | |
Preoperative treatment, n (%) | |||
Statins | 347 (51.7) | 20 (50) | 0.502 |
β-blockers | 216 (32.6) | 10 (26.3) | 0.058 |
ACEI/ARB | 333 (49.9) | 14 (35.9) | 0.072 |
Preoperative hemoglobin (g/dl) | 12.5±1.6 | 12.4±1.9 | 0.786 |
Preoperative hematocrit (%) | 39.3±4.3 | 39.1±4.8 | 0.820 |
Ejection fraction, (%) | 51.6±8.1 | 50.9±8.7 | 0.596 |
Glasgow prognostic score, n (%) | |||
GPS=0 | 459 (68.3) | 14 (35) | |
GPS≥1 | 213 (31.7) | 26 (65) | |
POAF developed patients, n (%) | 106 (15.8) | 15 (37.5) | |
Intensive Care Unit stay (days) | 3.3±1.4 | 3.7±2.9 | 0.136 |
In-hospital stay (days) | 6.8±4.1 | 6.9±5.1 | 0.822 |
EuroSCORE – European System for Cardiac Operative Risk Evaluation, CVA – cardiovascular accident; COPD – chronic obstructive pulmonary disease; DM – diabetes mellitus; CAD – coronary artery disease; ACEI/ARB – angiotensin converting enzyme/angiotensin receptor blocker; GPS – Glasgow prognostic score; POAF – post operative atrial fibrillation. |